StockMarketWire.com - Shield Therapeutics said that European distribution partner Norgine had launched its iron deficiency treatment in the UK.

Sheild in September licensed the so-called Feraccru treatment to Norgine in most European territories.

'Since announcing the licence agreement in September 2018, we have been working closely with Norgine to transfer knowledge and responsibilities from Shield to them and the UK launch demonstrates that this transition period is progressing well,' chief executive Carl Sterritt said.




At 1:10pm: [LON:STX] Shield Therapeutics Plc share price was 0p at 34p



Story provided by StockMarketWire.com